Baxter and COSMED partner in commercialization of Q-NRG+ device
Baxter and COSMED, a designer of metabolic systems for clinical and human performance applications, announced an agreement to commercialize Q-NRG+, a metabolic monitoring device utilizing indirect calorimetry technology. The agreement provides that Baxter will bring Q-NRG+ to 18 countries around the world with potential for further expansion. Q-NRG+ is expected to be available from Baxter in September as part of a phased launch in select European countries, Canada and Australia, with launches in additional markets pending future regulatory approval. Additional terms of the agreement were not disclosed. Q-NRG+ is designed to address barriers to rapidly and accurately measure a patient's resting energy expenditure.